As can be seen in Table 3, in the early breast cancer group, there were only two samples that were found positive for HER-2 in CTC both by the multiplex RT-qPCR and by the AdnaTest, while 202 samples were found negative by both assays. This evidence concerns the gene ERBB2 and breast carcinoma.